Jubilant Organosys, an integrated pharmaceutical industry player, has notified that its Bangalore-based subsidiary Jubilant Biosys Ltd, has entered into a drug discovery partnership with BioLeap, LLC, USA.

Under the relationship, BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform.

The partnership will provide customers with integrated pre-clinical drug discovery services from lead identification and optimization to IND (Investigational New Drug) candidate selection, for multiple therapeutic areas.